Companies › Syntrix Biosystems
1 active drug program in 11 registered trials: 7 Phase 1, 4 Phase 2; Hematology, Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SX-682 Interleukin-8 receptors, CXCR1/CXCR2 inhibitor | CXCR2, CXCR1 | Phase 2 | Metastatic Castration-resistant Prostate Cancer; Melanoma Stage III; Myelodysplastic Syndromes; Metastatic Lung Non-Small Cell Carcinoma … | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04477343 | SX-682 | Phase 1 | Pancreatic Ductal Adenocarcinoma | Oncology | Dec 2026 |
| NCT06622005 | SX-682 | Phase 1 | Recurrent Multiple Myeloma | Oncology | Apr 2027 |
| NCT03161431 | SX-682 | Phase 1 | Melanoma Stage III | Oncology | Jun 2027 |
| NCT06228053 | SX-682 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Oncology | Jun 2027 |
| NCT05570825 | SX-682 | Phase 2 | Metastatic Lung Non-Small Cell Carcinoma | Oncology | Jul 2027 |
| NCT06149481 | SX-682 | Phase 1 | Metastatic Colorectal Cancer | Oncology | Oct 2027 |
| NCT05604560 | SX-682 | Phase 2 | Pancreatic Cancer | Oncology | Dec 2027 |
| NCT04245397 | SX-682 | Phase 1 | Myelodysplastic Syndromes | Hematology | Mar 2028 |
| NCT07002320 | SX-682 | Phase 1 | Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | Oncology | Oct 2029 |
| NCT07322341 | SX-682 | Phase 2 | Advanced Lung Non-Small Cell Carcinoma | Oncology | Nov 2030 |
| NCT07667400 | SX-682 | Phase 1 | Head and Neck Cancer | Oncology | Oct 2036 |
Electra Therapeutics Servier Affaires Médicales Theravia Geron Shanghai Guangsheng Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.